N/A
Completed N=980
Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST)
Post Menopausal Women With Early Breast Cancer
Source: ClinicalTrials.gov NCT01050634 ↗
Enrolled (actual)
980
Serious AEs
1.2%
Results posted
Jul 2010
Primary outcomePrimary: Change From Baseline in International Breast Cancer Study Group (IBCSG) Linear Analogues Self-Assessment (LASA) Quality of Life (QoL) Core Questionnaire Scores — -5.82; -8.37; -8.22; -7.04 mm
Summary
Quality of life under therapy with Aromasin® (exemestane) according to IBCSG (International Breast Cancer Study Group) questionnaire.
Change of the endometrium after switching from tamoxifen to Aromasin® (exemestane).
Deeper knowledge of Adverse Events during routine administration.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in International Breast Cancer Study Group (IBCSG) Linear Analogues Self-Assessment (LASA) Quality of Life (QoL) Core Questionnaire Scores |
-5.82; -8.37; -8.22; -7.04; -5.98; -2.06 | — |
| PRIMARY Change From Baseline in Thickness of Endometrium |
-1.1 | — |
| PRIMARY Change From Baseline in IBCSG LASA Items Scores - QoL Module 24-26 |
-5.22; -7.44; -3.45; -4.98; -1.70; -5.35 | — |
| PRIMARY Change From Baseline in 12-Item Short Form Health Survey (SF-12) Summary Subscales (Physical Summary Scale Derived From Items 1-5, 8 and Mental Summary Scale Derived From Items 6, 7, 9-11) Scores |
2.93; 2.02 | — |
| PRIMARY Change From Baseline in IBCSG Vaginal Symptoms - QoL Module 24-26 |
-10.2 | — |
Eligibility Criteria
Inclusion Criteria
- Early Breast Cancer, post-menopausal, 2-3 yrs adjuvant tamoxifen therapy.
Exclusion Criteria
- Not applicable.
Data sourced from ClinicalTrials.gov (NCT01050634). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.